Abstract: Disclosed is a system for determining fecundity of an embryo utilizing a non¬ invasive grading of early stage embryos (pre-hatching) based upon specific gravity, density and/or estimated weight. The system allows 100% recovery of embryos and can detect differences in growth potential at the earliest stages of development. The system may further enhance the development of embryos by utilization of microfluidic effects during use. The disclosed system supports a wide variety of scenarios for human and animal reproductive technologies and related products and services.
Abstract: In some embodiments, the invention provides a method for identifying a patient suffering from or suspected of suffering in from a disease associated with the cardiovascular system that is having a subnormal response to the treatment for the disease comprising: subjecting a blood sample from a patient being treated for a disease to a viscoelastic analysis in the presence of a known amount of a thrombolytic agent, to obtain a coagulation characteristic value of the patient; and comparing the coagulation characteristic value of the patient to a coagulation characteristic value of a healthy individual, wherein a difference in the coagulation characteristic value of the patient as compared to the coagulation characteristic value of the healthy individual identifies the patient as a patient having a subnormal response to treatment.
Type:
Grant
Filed:
May 11, 2017
Date of Patent:
November 9, 2021
Assignee:
The Regents of the University of Colorado, a body corporate
Abstract: Provided herein are transmucosal and transdermal delivery systems comprising: at least one non-ionic surfactant; at least one polyol; and at least one active agent; and optionally further comprising at least one oil. In particular embodiments, the delivery system has an average particle size of from about 5 nm to about 200 nm.
Type:
Grant
Filed:
March 2, 2016
Date of Patent:
November 2, 2021
Assignee:
Medlab Clinical U.S., Inc.
Inventors:
David A. Rutolo, Jr., Sean Michael Hall, Luis Vitetta, Yusi Zhou, Samantha Maree Coulson
Abstract: Methods for culturing filamentous fungi, in which the filamentous fungi are grown in a colloid of air and a fermentation medium, are provided. The methods result in more rapid and prolific growth of the filamentous fungus than has been achieved by previous methods. Biomats produced by the methods and air-medium colloids for use in the methods are also provided.
Type:
Grant
Filed:
December 10, 2020
Date of Patent:
October 19, 2021
Assignee:
The Fynder Group, Inc.
Inventors:
Michael John Harney, Richard Eugene Macur, Yuval Charles Avniel
Abstract: Methods of selecting a subject for treatment of amyotrophic lateral sclerosis (ALS) and methods of treatment for subjects having ALS or at risk of developing ALS are provided. The method of selecting subjects for treatment includes obtaining a biological sample from the subject, where the sample is obtained from the subject's gastrointestinal tract or skeletal muscle. The method further includes measuring a biomarker in the subject's sample and selecting the subject for treatment of ALS when the biomarker measurement in the subject's sample is lower or higher relative to a control measurement.
Type:
Grant
Filed:
May 11, 2015
Date of Patent:
October 12, 2021
Assignee:
Rush University Medical Center
Inventors:
Jun Sun, Jingsong Zhou, Shaoping Wu, Jianxun Yi
Abstract: Embodiments of the disclosure concern methods and compositions related to manipulation of the microbiome in an individual having at least one social behavior deficit. In particular embodiments, an individual has at least one social behavior deficit and was born from a mother who during pregnancy was obese, overweight, or on a high-fat diet during pregnancy or carries mutations associated with neurodevelopmental disorders. In specific embodiments, the individual having at least one social behavior deficit is provided an effective amount of Lactobacillus reuteri for the improvement of at least one symptom of a social behavior deficit.
Type:
Grant
Filed:
April 15, 2017
Date of Patent:
October 5, 2021
Assignee:
Baylor College of Medicine
Inventors:
Mauro Costa-Mattioli, Shelly Alexandra Buffington
Abstract: The present invention relates to a method for promoting insulin secretion comprising administering an effective amount of plasminogen to a subject; furthermore, the present invention relates to a medicament for promoting insulin secretion.
Abstract: Tissue repair compositions, particularly bone repair compositions, containing demineralized bone fragments and homogenized connective tissues, and methods for making the same. The compositions can be used in the form of an injectable gel, an injectable paste, a paste, a putty, or a rehydratable freeze-dried form.
Type:
Grant
Filed:
April 10, 2019
Date of Patent:
September 21, 2021
Assignee:
LifeNet Health
Inventors:
Leila Masinaei, Lloyd Wolfinbarger, Jr.
Abstract: The present disclosure relates to methods of treating at least one symptom of a mental disorder or disease of the central nervous system in a subject by modulating the amount of GABA produced in the subject's gut. The present disclosure also relates to methods of culturing the bacterial strain new bacterial strains. Also disclosed are methods of identifying bacterial strains capable of producing GABA, and engineering strains to produce GABA.
Abstract: The invention provides methods of treating ?-galactosidase A deficiency. Dosage forms, methods of administration, and methods of analyzing human ?-galactosidase A are also included.
Type:
Grant
Filed:
February 14, 2019
Date of Patent:
September 14, 2021
Assignee:
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventors:
Douglas A. Treco, Kenneth Loveday, Marianne Borowski
Abstract: The invention relates to a lyophilized composition comprising a microbiota in its ecosystem, in particular stools, and a mixture of cryoprotectant agents comprising maltodextrin and trehalose, a capsule comprising said lyophilized composition, the use thereof, and methods for the production thereof.
Type:
Grant
Filed:
December 16, 2016
Date of Patent:
September 7, 2021
Assignees:
INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT, UNIVERSITE PARIS DESCARTES, UNIVERSITE PARIS DIDEROT—PARIS 7, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS
Abstract: The present invention relates to a test element for the detection of an analyte comprising an enzyme, wherein the enzyme is incorporated in a nanocapsule.
Abstract: A Lactobacillus species strain isolated from kimchi or human feces is described. The particular Bacillus species strain described is highly safe by being isolated from kimchi or human feces and has various functionalities, such as excellent blood sugar control activity, anti-obesity activity, blood cholesterol-lowering activity, blood neutral lipid-lowering activity, arteriosclerosis-inhibiting activity or inflammation-inhibiting activity. Accordingly, the particular Bacillus species strain described can be used as a useful food and drug material for preventing, alleviating or treating a metabolic syndrome including diabetes, obesity, fatty liver, glycosuria, hyperlipidemia, cardiovascular disease, hypertension, arteriosclerosis and/or diabetes, an inflammatory disease, and the like.
Type:
Grant
Filed:
September 7, 2016
Date of Patent:
August 31, 2021
Assignee:
UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY
Inventors:
Dong Hyun Kim, Myung Joo Han, Su Min Lim, Sang Yun Lee
Abstract: The present disclosure provides a method of assessing periorbital puffiness in a subject by determining if the subject exhibits pseudoherniation of one or more upper eyelid fat pads and/or one or more of the lower eyelid fat pads, determining if the subject exhibits one or more conditions selected from the group consisting of: edema of the fat pad, edema along the soft tissue of the upper and/or lower eyelids, malar mounds due to edema, malar edema, and mild festoons aggravated by edema, and scoring the periorbital puffiness from both determinations.
Abstract: Methods for generating serum-free and/or xenogen-free cardiac explant-derived stem cells (EDC) are provided. These methods may include providing an initial cardiac explant, which has been minced and digested; plating the initial cardiac explant; culturing the plated cardiac explant in serum-free and xenogen-free medium; harvesting EDC cells surrounding or emerging from the plated cardiac explant; and optionally performing static expansion of harvested EDC cells in serum-free and xenogen-free media. Serum-free and/or xenogen-free cardiac EDC cells produced by these methods, as well as methods and uses thereof for the treatment of heart failure in a subject in need thereof, are also provided.
Type:
Grant
Filed:
May 30, 2017
Date of Patent:
August 10, 2021
Assignee:
OTTAWA HEART INSTITUTE RESEARCH CORPORATION
Inventors:
Duncan J. Stewart, David Courtman, Seth Mount, Darryl Davis
Abstract: Disclosed is an abuse-deterrent pharmaceutical composition comprising a drug with an enzyme-reactive functional group, wherein the drug has an abuse potential, and an enzyme capable of reacting with the enzyme-reactive functional group (a drug-processing enzyme), wherein the drug with the enzyme-reactive functional group is contained in the pharmaceutical composition in a storage stable, enzyme-reactive state and under conditions wherein no enzymatic activity acts on the drug.
Type:
Grant
Filed:
February 28, 2017
Date of Patent:
August 3, 2021
Assignee:
G.L. PHARMA GMBH
Inventors:
Georg Guebitz, Katrin Greimel, Martin Brandauer, Daniela Huber, Klaus Bleymaier, Wolfgang Kroutil, Doris Lechner, Christof Wachter, Harald Wagner, Heimo Winkler
Abstract: Provided herein are compositions containing a lysosomal storage disorder replacement enzyme (LSDRE) and a dispersing agent for subcutaneous injection for treatment of lysosomal storage diseases. Kits and methods of treatment are also provided.
Abstract: The present invention concerns a lactic composition useful for the prevention or treatment of diarrhea such as antibiotic associated diarrhea or “tourista.” The composition according to the invention contains at least a bacterial strain selected from the group consisting of Lactobacillus acidophilus, Lactobacillus acidophilus I-1492, Lactobacillus casei and a mixture of thereof.
Abstract: The disclosure relates to isolated microorganisms—including novel strains of the microorganisms—microbial ensembles, and compositions comprising the same. Furthermore, the disclosure teaches methods of utilizing the described microorganisms, microbial compositions, and compositions comprising the same, in methods for modulating the agricultural production of ruminants. In particular aspects, the disclosure provides methods of increasing feed efficiency, and methods of decreasing acidosis.
Type:
Grant
Filed:
April 27, 2018
Date of Patent:
June 29, 2021
Assignee:
Native Microbials, Inc.
Inventors:
Mallory Embree, Cameron Martino, Norman Pitt, Jordan Embree, Corey Dodge